FY2025 · period end Dec '25 · from the 10-K filed Feb 26, 2026
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Revenue | $5.94B | $5.37B | $4.80B | $4.35B | $4.01B |
| Gross Profit | — | — | — | — | — |
| Operating Income | — | — | — | — | — |
| Net Income | $0.57B | $0.46B | $0.35B | $0.27B | $0.41B |
| EPS (Diluted) | $5.54 | $4.46 | $3.47 | $2.70 | $4.11 |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Total Assets | $7.09B | $6.53B | $6.10B | $5.64B | $6.86B |
| Total Liabilities | $3.81B | $3.69B | $3.81B | $3.77B | $4.47B |
| Stockholders' Equity | $3.22B | $2.79B | $2.26B | $1.83B | $2.36B |
| Cash & Equivalents | $0.07B | $0.09B | $0.07B | $0.02B | $0.05B |
| Total Debt | $2.45B | $2.36B | $2.69B | $2.74B | $3.24B |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Operating Cash Flow | — | — | — | $0.71B | $0.72B |
| Capital Expenditures | — | — | — | $0.56B | $0.52B |
| Free Cash Flow | — | — | — | $0.14B | $0.19B |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — |
| Operating Margin | 0.0% | 0.0% | 0.1% | 0.0% | — |
| Net Margin | 0.1% | 0.1% | 0.1% | 0.1% | 10.3% |
| Return on Equity | 18.8% | 18.1% | 17.2% | 13.0% | 17.5% |
| Return on Assets | 8.3% | 7.2% | 6.0% | 4.3% | 6.0% |
| Debt / Equity | 0.76× | 0.84× | 1.19× | 1.50× | 1.37× |
Showing the most recent 5 annual periods. Get 15 years of history on the Pro plan, or unlimited history back to 1993 plus the smart-money dataset and webhooks on Institutional.
| Form | Accession ID | Report Date | Filing Date | Accepted At | Source |
|---|---|---|---|---|---|
| 8-K | 0000785161-26-000195 | Aug 13, 2026 | Aug 13, 2026 | Aug 13, 2026 20:39 UTC | EDGAR |
| 10-Q | 0000785161-26-000186 | Jun 30, 2026 | Aug 7, 2026 | Aug 7, 2026 17:12 UTC | EDGAR |
| 8-K | 0000785161-26-000183 | Aug 5, 2026 | Aug 5, 2026 | Aug 5, 2026 20:23 UTC | EDGAR |
| 8-K | 0000785161-26-000161 | May 29, 2026 | Jun 1, 2026 | Jun 1, 2026 20:26 UTC | EDGAR |
| 8-K | 0000785161-26-000156 | May 14, 2026 | May 15, 2026 | May 15, 2026 19:24 UTC | EDGAR |
| 8-K | 0000785161-26-000151 | May 7, 2026 | May 11, 2026 | May 11, 2026 20:21 UTC | EDGAR |
| 10-Q | 0000785161-26-000130 | Mar 31, 2026 | May 1, 2026 | May 1, 2026 19:28 UTC | EDGAR |
| 8-K | 0000785161-26-000128 | Apr 30, 2026 | Apr 30, 2026 | Apr 30, 2026 20:24 UTC | EDGAR |
Direct links to SEC EDGAR. EHC has additional filings available on the SEC site.
6 numbers Encompass Health Corp later changed — same XBRL tag, both filings linked.
INCOME-PRETAX·FY 1995
Major restatementwas$142.6M
Revised up in a 10-K/A.
TOTAL-REVENUES·FY 1995
Major restatementwas$1.6B
Revised up in a 10-K/A. Any P/S built on the original was 22.3% too high.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest·FY 2020
Major restatementwas$472.6M
Revised down in a 10-K.
Net Income (Loss) Attributable to Parent·3 months to Dec 2017
Major restatementwas$60.6M
Revised up in a 10-K. Any P/E built on the original was 19.6% too high.
Revenue from Contract with Customer, Excluding Assessed Tax·FY 2020
Major restatementwas$4.6B
Revised down in a 10-K. Any P/S built on the original was 30.2% too low.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest·FY 2021
Major restatementwas$657.2M
Revised down in a 10-K.
EHC is not the only one.
See every restatement we've found across the market — or get an alert the next time EHC revises a number.
Restatements are detected by comparing every vintage of a fact across all of Encompass Health Corp's filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows EHC's most significant revisions, and a figure absent from it has not been certified as unrevised.
Who is buying and selling Encompass Health Corp — insider transactions from Forms 3/4/5/144 and institutional ownership from 13F, 13D, and 13G filings, point-in-time stamped like every other fact in the library. Traders read it as a positioning signal; risk desks read it as concentration.
No published research on EHC yet.
Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows, every figure pinned to its SEC filing. Be the first: run equity_research_brief on EHC and publish the result to your public profile.
Ask about Encompass Health Corp
Continue in Workspace — cited answers on EHC, a thesis you can score, or a signal on the next filing.
Open in WorkspaceGet 15 years of data
Quarterly and annual financials back to 2011 on Pro (1993 on Institutional). Point-in-time accurate with zero survivorship bias.
View plansQuery via Python SDK
Pull data into DuckDB with 3 lines of Python. Works in Jupyter notebooks, scripts, and CI pipelines.
SDK docsConnect via MCP Server
Wire Claude, Cursor, or Codex directly to live SEC data with a single Bearer token. No scraping, no glue code.
MCP docs